SubHero Banner
Text

Leqembi (lecanemab-irmb) – FDA accepts application for traditional approval

March 6, 2023 - Eisai and Biogen announced that the FDA has accepted their supplemental Biologics License Application (sBLA) for Leqembi (lecanemab-irmb), requesting the conversion of the accelerated approval of Leqembi to a traditional (full) approval.

Download PDF